Validation of a database on acrylamide for use in epidemiological studies

Department of Quality and Safety, Nestlé Research Center, Lausanne, Switzerland.
European journal of clinical nutrition (Impact Factor: 2.71). 03/2010; 64(5):534-40. DOI: 10.1038/ejcn.2010.17
Source: PubMed


Acrylamide, a probable human carcinogen, was detected in various heat-treated foods such as French fries and potato crisps. Recently, positive associations have been found between dietary acrylamide intakes, as estimated with a food frequency questionnaire using an acrylamide database, and cancer risk in some epidemiological studies. As acrylamide levels vary considerably within the same type of foods, a validation study was performed to investigate whether use of an acrylamide food database containing calculated mean acrylamide content, based on extensive sampling and chemical analysis of Dutch foods (several samples per food), can classify subjects with respect to true acrylamide intake.
We used the data from a 24-h duplicate diet study. The acrylamide content of 39 Dutch 24-h duplicate diets collected in 2004 was estimated using the mean acrylamide levels of foods available from the database and the menu list, on which the participants of the duplicate diet study had listed the amounts of individual foods and drinks in household units. Next, the acrylamide content of the total duplicate diets was analytically measured and correlated to the estimated acrylamide contents.
The Spearman's correlation coefficient between chemically determined acrylamide content and the calculated acrylamide content of the duplicate diets was 0.82 (P<0.001).
This study indicates that it is possible to classify subjects with respect to acrylamide intake if mean instead of actual content of each food is applied. The database can therefore be applied in epidemiological studies on acrylamide intake and cancer risk, such as the Netherlands Cohort Study on Diet and Cancer.

Download full-text


Available from: Erik J M Konings, Jul 11, 2014
  • Source
    • "The EU database was set up to permit monitoring of acrylamide levels in food products throughout the whole EU, which includes the UK. A recent validation study compared estimated acrylamide intake based on average acrylamide levels of food items, such as those available in the EU database, compared with chemically analysed content (Konings et al, 2010). The correlation between chemically determined acrylamide content and estimated acrylamide content was very high, indicating that using single acrylamide values for individual foods based on average values of several available samples, such as that reported in the EU database, results in a good rank ordering of most subjects, despite the large variation of acrylamide concentrations within single foods. "
    [Show abstract] [Hide abstract]
    ABSTRACT: No studies to date have demonstrated a clear association with breast cancer risk and dietary exposure to acrylamide.Methods:A 217-item food frequency questionnaire was used to estimate dietary acrylamide intake in 33,731 women aged 35-69 years from the UK Women's Cohort Study followed up for a median of 11 years. In all, 1084 incident breast cancers occurred during follow-up. There was no evidence of an overall association between acrylamide intake and breast cancer (hazard ratio=1.08 per 10 μg day(-1), 95% CI: 0.98-1.18, P(trend)=0.1). There was a suggestion of a possible weak positive association between dietary acrylamide intake and premenopausal breast cancer after adjustment for potential confounders (hazard ratio=1.2, 95% CI: 1.0-1.3, P(trend)=0.008). There was no suggestion of any association for postmenopausal breast cancer (hazard ratio=1.0, 95% CI: 0.9-1.1, P(trend)=0.99). There is no evidence of an association between dietary acrylamide intake and breast cancer. A weak association may exist with premenopausal breast cancer, but requires further investigation.
    Full-text · Article · Oct 2010 · British Journal of Cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: Information on the relation between acrylamide exposure and risk of pancreatic cancer is scanty and inconsistent. We investigated the issue in a case-control study conducted from 1991 to 2008 in Northern Italy. Cases were 326 patients with incident pancreatic cancer, admitted to major teaching and general hospitals. Controls were 652 subjects admitted to the same hospitals with acute non-neoplastic conditions. Acrylamide mean content of various food items was derived from international databases and Italian sources. Odds ratios (ORs) and 95% confidence intervals (CIs) of pancreatic cancer were derived using conditional logistic regression adjusted for several covariates, including energy intake. The ORs of pancreatic cancer for subsequent quintiles of acrylamide intake, as compared with the lowest one, were 1.48 (95% CI 0.88-2.50), 1.57 (95% CI 0.91-2.69), 1.70 (95% CI 0.98-2.96) and 1.49 (95% CI 0.83-2.70), with no trend in risk (P value 0.21). The OR for an increase in acrylamide intake of 10 μg/day was 1.01 (95% CI 0.92-1.10). No meaningful difference between ORs was found in strata of smoking habit, alcohol drinking, body mass index and other selected covariates. This study found no association between dietary acrylamide and pancreatic cancer in an Italian population.
    No preview · Article · Feb 2011 · Annals of Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Acrylamide has been associated to cancer risk in rodents, but data on humans are inconclusive. We thus carried out a critical review and meta-analysis of studies of exposure to acrylamide and cancer. We identified 586 publications, 25 presented relevant results. We conducted meta-analyses of studies of dietary intake based on random-effects models by calculating pooled relative risks (RR) and the corresponding 95% confidence intervals (CI). We combined results of occupational studies according to a fixed-effect model. The summary RRs for an increase of 10 μg/day of acrylamide intake were close to unity for all the cancers considered, ranging from 0.98 for esophageal cancer to 1.01 for colon, endometrial, ovarian and kidney cancer. None of the estimates was significant. Exclusion of one case-control study from Sweden resulted in a summary RR of kidney cancer of 1.04 (95% CI 1.00-1.08). The combined standardized mortality ratios for high occupational exposure were 1.67 (95% CI 0.83-2.99) for pancreatic cancer and 2.22 (95% CI 0.81-4.84) for kidney cancer. Available studies consistently suggest a lack of an increased risk of most types of cancer from exposure to acrylamide. The main association that requires further monitoring involves kidney cancer.
    Full-text · Article · Jun 2011 · Annals of Oncology
Show more